@article{article_1404919, title={Hypocalcemia in cancer patients}, journal={Pamukkale Medical Journal}, volume={17}, pages={596–599}, year={2024}, DOI={10.31362/patd.1404919}, author={Akay, Seval and Unal, Olcun Umit}, keywords={Hypocalcemia, hypomagnesemia, cancer treatment, chemotherapy, cisplatin}, abstract={The primary objective of this review is to provide a concise summary and critical appraisal of the current literature on the differential diagnosis and management of hypocalcemia. Calcium plays a crucial role in muscle function and neurotransmitter release. However, hypocalcemia, defined as serum calcium levels below 8 mg/dL (2.12 mmol/L), can affect various organs and systems and lead to a range of clinical symptoms. This condition can range from being completely asymptomatic to life-threatening situations.
Disorders responsible for hypocalcemia can be divided into two groups: those influenced by parathyroid hormone (PTH) and those not affected. In non-surgical and PTH-mediated forms, more comprehensive investigation is necessary to identify the underlying cause and determine appropriate treatment.
In cases of acute hypocalcemia, intravenous calcium infusion is required to rapidly increase calcium levels and correct symptoms. On the other hand, treatment of chronic hypocalcemia generally involves oral calcium and/or vitamin D supplementation.
In conclusion, this review specifically emphasizes iatrogenic (treatment-related) hypocalcemia while assessing the causes, dimensions, and management of hypocalcemia in cancer patients. Physicians’ familiarity with these conditions is crucial in treatment management.}, number={3}, publisher={Pamukkale University}, organization={Destekleyen kurum yoktur.}